DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Epirubicin (Epirubicin) - Serious Reactions - Suspected Cause - Side Effect Reports

 
 



Index of reports > Serious Reactions (153)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Epirubicin serious reactions. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 153   Next >>

Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20

Patient:

Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer

Epirubicin
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Herceptin
    Dosage: loading dose
    Indication: Breast Cancer

Herceptin
    Dosage: maintenance dose

Lapatinib
    Dosage: arm b
    Administration route: Oral
    Indication: Breast Cancer

Lapatinib
    Dosage: arm c
    Administration route: Oral

Paclitaxel
    Indication: Breast Cancer



Possible Epirubicin side effects in 74 year old male

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-16

Patient: 74 year old male

Reactions: Hepatitis C

Drug(s) suspected as cause:
Cisplatin
    Dosage: 60 mg/m2, cyclic
    Indication: Hepatic Neoplasm Malignant non-Resectable

Epirubicin
    Dosage: 50 mg/m2, cyclic
    Indication: Hepatic Neoplasm Malignant non-Resectable

Other drugs received by patient: Lipiodol



Possible Epirubicin side effects in 73 year old male

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-16

Patient: 73 year old male

Reactions: Hepatitis C

Drug(s) suspected as cause:
Cisplatin
    Dosage: 60 mg/m2, cyclic
    Indication: Hepatic Neoplasm Malignant non-Resectable

Epirubicin
    Dosage: 50 mg/m2, cyclic
    Indication: Hepatic Neoplasm Malignant non-Resectable

Other drugs received by patient: Lipiodol



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13

Patient: female

Reactions: Oesophageal Candidiasis

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2011-10-14
    End date: 2011-10-14

Cyclophosphamide
    Start date: 2011-09-16

Cyclophosphamide
    Start date: 2011-09-02

Cyclophosphamide
    Start date: 2011-09-30

Epirubicin
    Start date: 2011-09-16

Epirubicin
    Start date: 2011-09-30

Epirubicin
    Start date: 2011-09-02

Epirubicin
    Start date: 2011-10-14
    End date: 2011-10-14

Other drugs received by patient: Neupogen; Taxol; Tamoxifen Citrate; Docetaxel; Acetaminophen and Codeine Phosphate; Docetaxel; Acetaminophen and Codeine Phosphate



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-13

Patient:

Reactions: Dyspnoea, Brain Natriuretic Peptide Increased, Ejection Fraction Decreased, Nail Disorder, Cardiac Failure Congestive, Infusion Related Reaction

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: 500 mg/m2 for fac regimen and 600 mg/m2 for ac regimen
    Indication: Breast Cancer

Docetaxel
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
    Indication: Breast Cancer

Epirubicin
    Dosage: 75-100 mg/m2
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Paclitaxel
    Indication: Breast Cancer

Trastuzumab
    Dosage: 8 mg/kg followed by maintenance (md) 6 mg/kg every 3 wks or 4 mg/kg followed by 2 mg/kg weekly md
    Indication: Breast Cancer



Possible Epirubicin side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-10

Patient:

Reactions: Injection Site Vasculitis, Injection Site Pain, Injection Site Phlebitis

Drug(s) suspected as cause:
Epirubicin
    Indication: Breast Cancer

Fosaprepitant Dimeglumine
    Dosage: 150 mg, once
    Indication: Prophylaxis of Nausea and Vomiting
    Start date: 2012-02-06
    End date: 2012-02-06

Fosaprepitant Dimeglumine
    Dosage: 150 mg, once
    Start date: 2012-02-27
    End date: 2012-02-27

Fosaprepitant Dimeglumine
    Dosage: 150 mg, once
    Start date: 2012-03-19
    End date: 2012-03-19

Other drugs received by patient: Cyclophosphamide



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-09

Patient:

Reactions: Brain Natriuretic Peptide Increased, Dyspnoea, Ejection Fraction Decreased, Nail Disorder, Cardiac Failure Congestive, Infusion Related Reaction

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 mg/m2 for fac regimen and 600 mg/m2 for ac regimen
    Indication: Breast Cancer

Docetaxel
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
    Indication: Breast Cancer

Epirubicin
    Dosage: 75-100 mg/m2
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Paclitaxel
    Indication: Breast Cancer

Trastuzumab
    Dosage: 8 mg/kg followed by maintenance (md) 6 mg/kg every 3 wks or 4 mg/kg followed by 2 mg/kg weekly md
    Indication: Breast Cancer



Possible Epirubicin side effects in 74 year old male

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-09

Patient: 74 year old male

Reactions: Hepatitis C

Drug(s) suspected as cause:
Cisplatin
    Dosage: 60 mg/m2
    Indication: Hepatic Neoplasm Malignant non-Resectable

Epirubicin
    Dosage: 50 mg/m2
    Indication: Hepatic Neoplasm Malignant non-Resectable

Other drugs received by patient: Lipiodol



Possible Epirubicin side effects in 73 year old male

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-09

Patient: 73 year old male

Reactions: Hepatitis C

Drug(s) suspected as cause:
Cisplatin
    Dosage: 60 mg/m2
    Indication: Hepatic Neoplasm Malignant non-Resectable

Epirubicin
    Dosage: 50 mg/m2
    Indication: Hepatic Neoplasm Malignant non-Resectable

Other drugs received by patient: Lipiodol



Possible Epirubicin side effects in

Reported by a consumer/non-health professional from Canada on 2012-07-30

Patient:

Reactions: Disease Progression

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Product Used FOR Unknown Indication

Epirubicin
    Indication: Product Used FOR Unknown Indication

Fluorouracil
    Indication: Product Used FOR Unknown Indication

Xeloda
    Indication: Product Used FOR Unknown Indication



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-09

Patient: female

Reactions: Drug Intolerance, Tongue Neoplasm Malignant Stage Unspecified

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Neoplasm
    Start date: 2011-08-01

Cyclophosphamide
    Dosage: 14 days on 21 days
    Start date: 2011-02-01
    End date: 2011-07-01

Cyclophosphamide
    Start date: 2004-12-03
    End date: 2005-02-02

Doxorubicin HCL
    Dosage: 9 courses
    Indication: Product Used FOR Unknown Indication
    Start date: 2009-02-19
    End date: 2009-11-05

Doxorubicin HCL
    Dosage: 8 courses
    Start date: 2007-11-27
    End date: 2008-06-24

Epirubicin
    Indication: Product Used FOR Unknown Indication
    Start date: 2004-12-03
    End date: 2005-02-02

Fluorouracil
    Indication: Product Used FOR Unknown Indication
    Start date: 2004-12-03
    End date: 2005-02-02

Taxotere
    Indication: Product Used FOR Unknown Indication
    Start date: 2005-03-08
    End date: 2005-04-19

Other drugs received by patient: Aromasin; Navoban; Xeloda; Faslodex; Estracyt; Femara; Arimidex; Navelbine



Possible Epirubicin side effects in 63 year old male

Reported by a physician from Poland on 2012-06-27

Patient: 63 year old male

Reactions: Dyspnoea, Palmar-Plantar Erythrodysaesthesia Syndrome, Pleural Effusion, General Physical Health Deterioration, Neutropenia, Polyneuropathy, Disease Progression

Adverse event resulted in: death

Drug(s) suspected as cause:
Capecitabine
    Indication: Product Used FOR Unknown Indication

Epirubicin
    Indication: Product Used FOR Unknown Indication

Oxaliplatin
    Indication: Product Used FOR Unknown Indication



Possible Epirubicin side effects in female

Reported by a physician from Denmark on 2012-06-26

Patient: female

Reactions: Activities of Daily Living Impaired, Sensory Disturbance, Pain

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: unk
    Indication: Breast Cancer

Docetaxel
    Dosage: unk
    Indication: Breast Cancer

Epirubicin
    Dosage: unk
    Indication: Breast Cancer

Fluorouracil
    Dosage: unk
    Indication: Breast Cancer



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-06-25

Patient:

Reactions: Neutropenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (600 mg/m2 (every 3 weeks))
    Indication: Breast Cancer

Docetaxel
    Dosage: (100 mg/m2 (every 3 weeks))
    Indication: Breast Cancer

Epirubicin
    Dosage: (100 mg/m2 (every 3 weeks))
    Indication: Breast Cancer

Fluorouracil
    Dosage: (600 mg/m2 (every 3 weeks))
    Indication: Breast Cancer

Other drugs received by patient: Filgrastim



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-18

Patient:

Reactions: Vomiting

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Breast Cancer Stage III

Epirubicin
    Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Breast Cancer Stage III

Fluorouracil
    Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
    Indication: Breast Cancer Stage III



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Nausea

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 mg/m2 every three weeks intravenous not otherwise specified
    Indication: Inflammatory Carcinoma of Breast Stage III

Epirubicin
    Dosage: 100 mg/m2 every three weeks intravenous (not otherwise specified
    Indication: Inflammatory Carcinoma of Breast Stage III

Fluorouracil
    Dosage: 500 mg/m2 every three weeks intravenous bolus
    Indication: Inflammatory Carcinoma of Breast Stage III



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Hyperbilirubinaemia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Breast Cancer Stage III

Epirubicin
    Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Breast Cancer Stage III

Fluorouracil
    Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
    Indication: Breast Cancer Stage III



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Transaminases Increased

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Breast Cancer Stage III

Epirubicin
    Dosage: (100 mg/m2 (every three weeks) intravenous bolus)
    Indication: Breast Cancer Stage III

Fluorouracil
    Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
    Indication: Breast Cancer Stage III



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-06-15

Patient: female

Reactions: Alopecia, Neutropenia, Constipation

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2011-06-25
    End date: 2011-09-03

Epirubicin
    Start date: 2011-06-25
    End date: 2011-09-03

Fluorouracil
    Start date: 2011-06-25
    End date: 2011-09-03

Other drugs received by patient: Levothyroxine Sodium



Possible Epirubicin side effects in

Reported by a individual with unspecified qualification from Egypt on 2012-06-15

Patient:

Reactions: Neutropenia, Haematotoxicity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Inflammatory Carcinoma of Breast Stage III

Epirubicin
    Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Inflammatory Carcinoma of Breast Stage III

Fluorouracil
    Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
    Indication: Inflammatory Carcinoma of Breast Stage III



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Vomiting

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified)
    Indication: Inflammatory Carcinoma of Breast Stage III

Epirubicin
    Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified)
    Indication: Inflammatory Carcinoma of Breast Stage III

Fluorouracil
    Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
    Indication: Inflammatory Carcinoma of Breast Stage III



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Menstruation Irregular

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Breast Cancer Stage III

Epirubicin
    Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Breast Cancer Stage III

Fluorouracil
    Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
    Indication: Breast Cancer Stage III



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-06-15

Patient: female

Reactions: Hypertransaminasaemia

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2011-06-25
    End date: 2011-09-03

Epirubicin
    Indication: Breast Cancer
    Start date: 2011-06-25
    End date: 2011-09-03

Fluorouracil
    Indication: Breast Cancer
    Start date: 2011-06-25
    End date: 2011-09-03

Other drugs received by patient: Levothyroxine Sodium



Possible Epirubicin side effects in female

Reported by a individual with unspecified qualification from Egypt on 2012-06-15

Patient: female

Reactions: Menstruation Irregular

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Inflammatory Carcinoma of Breast Stage III

Epirubicin
    Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
    Indication: Inflammatory Carcinoma of Breast Stage III

Fluorouracil
    Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
    Indication: Inflammatory Carcinoma of Breast Stage III



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Anaemia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified)
    Indication: Inflammatory Carcinoma of Breast Stage III

Epirubicin
    Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified)
    Indication: Inflammatory Carcinoma of Breast Stage III

Fluorouracil
    Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
    Indication: Inflammatory Carcinoma of Breast Stage III



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Neutropenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 mg/m2 (every three weeks) intravenous (not otherwise specified)
    Indication: Inflammatory Carcinoma of Breast Stage III

Epirubicin
    Dosage: 100 mg/m2 (every three weeks) intravenous (not otherwise specified)
    Indication: Inflammatory Carcinoma of Breast Stage III

Fluorouracil
    Dosage: 500 mg/m2 (every three weeks) intravenous bolus
    Indication: Inflammatory Carcinoma of Breast Stage III



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Febrile Neutropenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 mg/m2 every three weeks intravenous not otherwise specified
    Indication: Inflammatory Carcinoma of Breast Stage III

Epirubicin
    Dosage: 100 mg/m2 every three weeks intravenous not other wise
    Indication: Inflammatory Carcinoma of Breast Stage III

Fluorouracil
    Dosage: 500 mg/m2 every three week (intravenously bolus)
    Indication: Inflammatory Carcinoma of Breast Stage III



Possible Epirubicin side effects in 60 year old female

Reported by a physician from Japan on 2012-06-15

Patient: 60 year old female

Reactions: Injection Site Vasculitis, Injection Site Pain, Injection Site Phlebitis

Drug(s) suspected as cause:
Epirubicin
    Indication: Breast Cancer

Fosaprepitant Dimeglumine
    Indication: Prophylaxis of Nausea and Vomiting
    Start date: 2012-02-06
    End date: 2012-02-06

Fosaprepitant Dimeglumine
    Start date: 2012-02-27
    End date: 2012-02-27

Fosaprepitant Dimeglumine
    Start date: 2012-03-19
    End date: 2012-03-19

Other drugs received by patient: Cyclophosphamide



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15

Patient:

Reactions: Nausea

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 mg/m2, every thrree weeks, intravenous
    Indication: Inflammatory Carcinoma of Breast Stage III

Epirubicin
    Dosage: 100 mg/m2, every three weeks, intravenous
    Indication: Inflammatory Carcinoma of Breast Stage III

Fluorouracil
    Dosage: 500 mg/m2, every three weeks, intravenous bolus
    Indication: Inflammatory Carcinoma of Breast Stage III



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-06-15

Patient: female

Reactions: Breast Cancer, Maternal Exposure During Pregnancy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2007-01-01
    End date: 2007-01-01

Epirubicin
    Indication: Breast Cancer
    Start date: 2007-01-01
    End date: 2007-01-01

Fluorouracil
    Indication: Breast Cancer
    Start date: 2007-01-01
    End date: 2007-01-01



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014